Fact · healthcare · 2022-23
Total health expenditure as share of GDP (excl. COVID-19 related expenditure)
醫療衞生總開支佔GDP（撇除新冠相關開支）
Figure and reference date
8.4% (FY2022-23, excl. COVID)
8.4%（2022-23 撇除新冠）
Notes and definition
Hong Kong Yearbook 2024, citing the domestic health accounts: total health expenditure as a share of GDP in FY2022-23 after removing COVID-19 related expenditure. The same page also carries the public share of total health expenditure, which is a different indicator.
There is more than one official basis
Total health expenditure as a share of GDP
Why are there two official percentages for total health expenditure as a share of GDP in the same financial year?
The same question has 2 official bases; their figures and scopes cannot be added together or swapped.
（口徑對照頁目前只有中文版：/calibre#health-expenditure-gdp）
Other figures in this group (healthcare)
Figures in the same group are not necessarily additive — check the basis note above first. Healthcare expenditure & pharmaceuticals.
| Item / 項目 | Figure / 數字 | As of / 時點 | Source / 來源 |
|---|---|---|---|
| Total health expenditure as share of GDP 本地醫療衞生經費佔 GDP 比例 | 8.3% (FY2023-24) 8.3%（2023-24年度） Health Bureau domestic health accounts: HK$251.2bn recurring, HK$33,334 per capita. | 2024 | Health Bureau: domestic health accounts |
| Statutory lists of Chinese herbal medicines 中藥材法定名錄總數 | 605 items (Schedule 1: 31 toxic; Schedule 2: 574 common) 605 種（附表1劇性／烈性31種＋附表2常用574種） Chinese Medicines Ordinance (Cap. 549) schedules. | 2023-01 | Department of Health Chinese Medicine Regulatory Office: statutory lists of Chinese herbal medicines |
| Total health expenditure as share of GDP 醫療衞生總開支佔GDP | 10.0% (FY2022-23 incl. COVID) 10.0%（2022-23 含新冠） Domestic health accounts, total expenditure basis (including COVID-19 related expenditure); the official figure for the same indicator after removing COVID-19 related expenditure is a separate fact entry, health-gdp-2022-23-excl-covid. | 2022-23 | Health Bureau: domestic health accounts |
| "1+" mechanism approved drugs 「1+」新藥審批數目 | 22 (to 31 Aug 2026) 22 款（截至2026-08-31） Applies to new drugs with local clinical support; count grows over time. | 2026-08-31 | Pharmacy and Poisons Board: "1+" new drug approval mechanism |
How to cite this figure
Hong Kong Story, “Total health expenditure as share of GDP (excl. COVID-19 related expenditure)”, https://hongkongstory.org/en/facts/health-gdp-2022-23-excl-covid, data as at 2022-23 (retrieved ＿).
中文：香港紀事館，〈醫療衞生總開支佔GDP（撇除新冠相關開支）〉，https://hongkongstory.org/facts/health-gdp-2022-23-excl-covid，資料時點 2022-23（查閱日期 ＿）。
Machine-readable: /api/v1/facts.json (id = health-gdp-2022-23-excl-covid) · OpenAPI 3.1 ·/llms.txt
Registered source
Hong Kong Yearbook 2024, Chapter 19: Health
Information Services Department
The official document carries no registered publication date, so only the retrieval date 2026-10-21 is given — no publication year is invented.
This site is a secondary compilation: the official text prevails. If the figure above differs from the official document, the official document is correct.